Kornimate/medical-research-clean huggingface dataset:
hemoadsorption for prevention of vasodilatory shock in cardiac surgery patients with infective endocarditis

Conditions: Infective Endocarditis

Summary: infective endocarditis (ie) is associated with high hospital mortality for various reasons; one of them is circulatory failure in patients who undergo cardiac surgery for ie. one discussed reason underlying circulatory failure during surgery is the release of vasodilatatory mediators and cytokines. this study examines the efficacy and safety of a hemoadsorption filter which is approved for the reduction of the concentration of cytokines in the bloodstream.

the investigators assume a common standard deviation of 3.8 points and that a 1.4-point lower sofa score in the intervention group is of clinical relevance.

Eligibility criteria:
inclusion criteria: * patients with infective endocarditis (according to duke criteria) undergoing cardiac surgery * informed consent * age ≥18 years exclusion criteria: * euroscoreii ≤ 3 * current participation in another interventional trial * pregnancy * current immunosuppressive or immunomodulatory therapy (with dosing of glucocorticoids over cushing threshold) * previous participation in the remove study

Keywords: vasodilatory shock hemoadsorption cardiac surgery cytokines
shaolin dan tian breathing fosters relaxed and attentive mind

Conditions: Attention; Electroencephalography

Summary: the present study aimed to utilize these well-known neuroelectrophysiological techniques to investigate the relatively less studied shaolin dan tian breathing (dtb) technique.

neuroelectrophysiological studies on various types of meditative breathing revealed its association with either a relaxing (i.e., enhanced alpha asymmetry) or an attentive state (i.e., enhanced intra- and inter-hemispheric theta coherence). the present study aimed to utilize these well-known neuroelectrophysiological techniques to investigate the relatively less studied shaolin dan tian breathing (dtb) technique. this technique consists of two components -- passive dtb and active dtb, and is considered not only as a relaxation exercise but also a form of qigong. based upon some pilot neuroimaging data and clinical observation, it was hypothesized that after familiarizing with the method, practicing dtb can induce both relaxing and attentive states. twenty-two adults received training on the dtb (experimental group) for one month. they were instructed to practice the technique daily, and at each practice, until they felt warm and/or relaxed. twenty age-, gender- and education-matched adults receiving conventional progressive muscle relaxation training were recruited as control. all participation was voluntary. quantitative eeg and bio-physiological data were collected at baseline and post training. eyes-closed resting eeg data before and immediately after each type of breathing were obtained individually at two time points.

Eligibility criteria:
inclusion criteria: * healthy controls * age 20 to 60 years exclusion criteria: * history of head injury, * seizure, * stroke, * other cns diseases or psychiatric illnesses of psychosis or mania.

Keywords: dan tian breathing physiological measurement progressive muscle relaxation monitoring, physiologic
open-label study of adalimumab in japanese subjects with hidradenitis suppurativa

Conditions: Hidradenitis Suppurativa

Summary: this study investigates efficacy, safety and pharmacokinetics of adalimumab in japanese subjects with moderate to severe hidradenitis suppurativa (hs).

prior to initiation of this study, global phase 2b study and pivotal phase iii studies were completed in the western countries and market authorization of adalimumab was approved in united states (us) and european union (eu) for the treatment of subjects with hs. the differences between this study and global studies include sample size, study design, duration, and race.

Eligibility criteria:
inclusion criteria: * participant must have a diagnosis of hs; * participant must have any hs symptom at least 6 months prior to baseline; * hs lesions must be present in at least 2 distinct anatomic areas, one of which must be hurley stage ii or hurley stage iii; * participant must have stable hs for at least 2 months (60 days) prior to screening and also at the baseline visit; * participant must have a total abscess and inflammatory nodule (an) count of greater than or equal to 3 at the baseline visit. exclusion criteria: * prior treatment with adalimumab or other anti-tumor necrosis factor (tnf) therapy or participation in adalimumab trial; * any other active skin lesion or condition that may interfere with assessment of hs; * participants received antibiotic treatment for hs within 28 days prior to the baseline visit other than those allowed per protocol. participant on permitted oral antibiotic treatment (doxycycline or minocycline only) for hs who have not been on a stable dose for at least 28 days prior to the baseline visit; * participants received prescription topical therapies for the treatment for hs within 14 days prior to the baseline visit; * participants received systemic non-biologic therapies with potential therapeutic impact for hs less than 28 days prior to the baseline visit; * participants received oral concomitant analgesics (non-opioids and opioids) for hs-related pain within 14 days prior to the baseline visit.

Keywords: efficacy safety adalimumab japanese participants
study the safety and effectiveness of tadalafil on high blood pressure in the blood vessel going from the heart to the lungs

Conditions: Hypertension, Pulmonary

Summary: study to determine the long term safety of tadalafil in patients with increased blood pressure in the blood vessel that carries blood from the right heart to the lungs and to see if it will keep the disease from getting worse.


Eligibility criteria:
inclusion criteria: * must have participated and discontinued in the previous pah placebo controlled study due to clinical worsening on placebo or tadalafil 2.5 mg, 10mg, or 20 mg * must have completed week 16 of the previous pah study and had either no clinical worsening or became clinically worse at the week 16 visit on placebo or tadalafil 2.5 mg, 10mg, or 20 mg * females who have a negative urine pregnancy test and are willing to use 2 types of birth control * be 12 years or older (country specific regulations apply) with parental approval exclusion criteria: * participated in the placebo controlled study and had clinical worsening on 40 mg tadalafil * have left-sided heart disease * have a musculoskeletal disorder that limits being able to get around * nitrate use * certain current systemic treatments
comparison of remimazolam and propofol for recovery of ambulatory upper airway surgery

Conditions: Laryngeal Disease; Pharyngeal Diseases; Oral Cavity Disease; Nasal Disease

Summary: the purpose of this study is to compare the effects of remimazolam and propofol on postoperative recovery time, complications, and safety in patients undergoing ambulatory upper airway surgery under general anesthesia.

patients scheduled for ambulatory upper airway (including nasal cavity, oral cavity, pharynx, larynx) surgery and who agree to participate in the study will be randomly assigned to the remimazolam group and the propofol group. in the remimazolam group, general anesthesia is induced and maintained by continuous infusion of remimazolam and remifentanil. once the surgery is completed, general anesthesia is recovered with flumazenil. in the propofol group, general anesthesia is induced and maintained by continuous infusion of propofol and remifentanil using a target concentration controlled infusion method. in both groups, rocuronium is used for neuromuscular blokade, and sugammadex is used for reversal of neuromuscular blockade. when the surgery is completed, recovery time, occurrence of adverse events, and anesthesia recovery indicators are examined in 3 stages: in the operating room, while staying in the post-anesthesia care unit(pacu), and while staying in the day surgery center.

Eligibility criteria:
inclusion criteria: * adult patients (age 19 or older) undergoing ambulatory upper respiratory tract (nasal cavity, oral cavity, pharynx, larynx) surgery under general anesthesia * american society of anesthesiologists physical class classification i, ii, and iii exclusion criteria: * patients who refused to participate in the study * pregnant patients * patients with a history of hypersensitivity to drugs or additives used during surgery * patients with acute narrow-angle glaucoma * alcohol or drug dependent patients * patients with child-pugh class c liver dysfunction

Keywords: remimazolam upper airway surgery ambulatory surgery
clinical evaluation of new biomarkers for ischemic cerebrovascular disease

Conditions: Ischemic Stroke; Ischemic Cerebrovascular Disease

Summary: the goal of this single-center prospective observational study is to identify and evaluate new biomarkers for ischemic cerebrovascular disease (icvd) to aid in early diagnosis, individualized treatment planning, and prognosis prediction in affected patients. the main questions it aims to answer are: can specific biomarkers help in identifying high-risk individuals before disease onset? can these biomarkers predict disease progression and treatment response? researchers will compare patients diagnosed with icvd and healthy controls from a medical check-up center to assess differences in biomarker expression and their clinical significance. participants will: provide blood, cerebrospinal fluid, urine, and stool samples for biomarker analysis. undergo clinical imaging (ct, mri, pet-ct) and functional assessments. be followed up at 3, 6, 12, 24, 36, and 48 months for clinical outcomes and biomarker changes. this study aims to develop a comprehensive biomarker-based prediction model to enhance the diagnosis and management of ischemic cerebrovascular disease.

the detaited information about this trial is described below 1. quality assurance: the research proposal is reviewed by an independent research panel. if the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed data sharing agreement. 2. data check: researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. 3. source data verification: medical records, electronic case report forms, and imaging would be processed by certified neurologists.

Eligibility criteria:
inclusion criteria: * ischemic cerebrovascular disease has been proved by clinical symptoms and imaging examinations,including transient ischemic attack, cerebral ischemic stroke, steal syndrome, chronic cerebral hypoperfusion, ect al. * sex and age-matched healthy individuals exclusion criteria: * brain ct or mri showing cerebral hemorrhage (excluded ischemic stroke with hemorrhage transformation) * with severe systemic disease, are expected to survive \< 3 months * patients will not able to provide continuous follow-up information
double-blind, randomized trial of prax-628 in adults with focal seizures to evaluate efficacy and safety (power1)

Conditions: Focal Seizure

Summary: a double-blind, randomized, multicenter, trial evaluating the efficacy and safety of prax-628 in adults with focal seizures (power1)

prax-628-321 (power1) is a double-blind, randomized, multicenter, trial to evaluate the efficacy and safety of prax-628 in adults who can attest to concurrently taking at least 1, but no more than 3 acceptable anti-seizure medications.

Eligibility criteria:
inclusion criteria: 1. a diagnosis of focal onset epilepsy according to the international league against epilepsy (ilae) classification of epilepsy. 2. past evidence by computed tomography (ct) or magnetic resonance imaging (mri) that has ruled out a progressive cause of epilepsy in the judgement of the investigator and/or in consultation with the medical monitor. exclusion criteria: 1. subject has had any of the of the following within the 12-month period preceding trial entry: history of pseudo or psychogenic seizures, cluster seizures where the individual seizures cannot be counted, an episode of convulsive status epilepticus requiring hospitalization and intubation, or subject only has focal seizures with awareness that do not have motor activity. 2. planned epilepsy surgery during the course of the clinical trial. 3. history of neurosurgery for seizures \<1 year prior to enrollment, or radiosurgery \<2 years prior to enrollment or vagus nerve stimulation (vns) implantation. 4. history of schizophrenia, obsessive-compulsive disorder, or other serious mental health disorders. 5. history of malignancy, myeloproliferative or lymphoproliferative disorders within the past 5 years are excluded. 6. history of cardiac disease(s)/cardiac conduction disorders/or cardiac structural abnormality(ies). 7. has a positive test result or a known history of a positive test result for human immunodeficiency virus (hiv), hepatitis b surface antigen (hbsag), or anti-hepatitis c virus (hcv) antibody at screening. 8. is pregnant or is breastfeeding at the time of screening or has a positive serum pregnancy test at screening or is planning to become pregnant during the clinical trial or within 14 days of the last study drug dose. 9. has received any other experimental or investigational drug, device or other therapy within 30 days or 5 half-lives (whichever is longer) prior to screening, or any prior use of gene therapy.

Keywords: focal seizure
telestroke 2: prehospital triage of patients with suspected stroke using onsite mobile telemedicine

Conditions: Stroke, Acute

Summary: this study is to investigate clinical efficacy of the pre-hospital triage of patients with suspected acute stroke by using advanced telecommunication tools with digital audio and video real-time streaming.

one of today's main challenges in stroke medicine is to further decrease event-to-treatment-time. on-site, pre-hospital, clinical assessment of patients with suspected acute stroke can optimize further diagnostic and treatment pathways after patient arrival at the dedicated stroke center. a telemedical approach (interactive video and audio streaming) allows time efficient pre-hospital triage, via patient evaluation by simple, pre-defined assessment measures and a standardized questionnaire. this study is to investigate clinical efficacy of the pre-hospital triage of patients with suspected acute stroke by using advanced telecommunication tools with digital audio and video real-time streaming.

Eligibility criteria:
inclusion criteria: * suspected acute stroke as per the first judgement of the paramedics on-site exclusion criteria: * patients with a known history of epilepsia or non-epileptic seizures * patients after/while displaying an epileptic seizure * recent head trauma * patient with a reduced glasgow coma scale or other condition not allowing rapid arterial occlusion evaluation (race) examination

Keywords: pre-hospital triage stroke, suspected telemedicine telemedical triage door-to-treatment-time
treating depression with text messaging

Conditions: Moderate Depression

Summary: the purpose of the research study is to investigate whether cbt-txt, a counseling program delivered by text messages is effective in stopping or reducing depressive symptoms. cbt-txt is based on a counseling program that has been proven to reduce depression when delivered in-person and on the web, but has not yet been tested or shown to be effective when delivered by text.

after being informed about the study and potential risks, participants will complete online screening assessments. once eligibility is confirmed, participants will be randomized either to the intervention group or to the waitlist-control group. those who are randomized to the intervention group will receive the 8-week text intervention via smartphone and complete assessments at baseline, 1 month, 2 months, and 3 months. those who are randomized to the waitlist-control group will only complete the assessments at baseline, 1 month, 2 months, and 3 months. participants who are initially assigned to the waitlist-control group can choose to receive the text intervention once their 3-month participation is complete.

Eligibility criteria:
inclusion criteria: * 18 to 25 years old * a score of at least 5 on the phq-9 (indicating elevated depression symptoms exclusion criteria: * treatment for depression during the past three months * endorse suicide ideation on the phq-9\* * lack of access to a text-capable phone * unable or unwilling to commit to two months of follow-up * not fluent in english.

Keywords: cognitive behavioral therapy text-based intervention
improving sleep with the far-infrared emitting pyjamas

Conditions: Sleep Disorder

Summary: the aim of this study is to explore the effects of a far-infrared emitting pyjamas on improving sleep in adults with poor sleep.

objectives: to explore the effects of a far-infrared emitting pyjamas on improving sleep in adults with poor sleep. hypothesis: subjects who wear the far-infrared emitting pyjamas (fir pyjamas) will have greater improvement in sleep quality than the subjects in sham pyjamas control group (sham-pyjamas) at 2, 4 and 6 weeks. design and subjects: a pilot randomized sham-controlled trial. subjects with subjective sleep complaints will be recruited from the community. 40 subjects will be randomized to far-infrared emitting pyjamas and sham-pyjamas groups in a 1: 1 ratio. study instrument: pittsburgh sleep quality index (psqi) will be used as an overall evaluation of sleep quality. interventions: subjects in the fir pyjamas group will received pyjamas with far-infrared emitting features and will wear it every night for 6 weeks; subjects in the sham-pyjamas group will receive pyjamas in identical appearance without far-infrared emitting features. outcome measures: the primary outcome measure is the psqi score. other measures include insomnia severity index (isi), sleep parameters derived from 7-day sleep diary, hospital anxiety and depression scale (hads), epworth sleepiness scale (ess) and satisfaction with life scale (swls) at 2, 4 and 6 weeks. acceptability of the far-infrared emitting pyjamas will also be evaluated. data analysis: differences in the questionnaire scores, subjective sleep parameters will be examined using a mixed-effects model. clinical significance of sleep improvement between two groups will be compared with chi-squared test.

Eligibility criteria:
inclusion criteria: * chinese hong kong residents who are able to read chinese; * aged 18 - 65 years; * subjective sleep complaints of having difficulties in falling asleep, difficulties in staying asleep, or early morning awakening with consequences for daily life for at least 3 months. * pittsburgh sleep quality index total score of at least 5 indicating sleep disturbance with 89.6% sensitivity and 86.5% specificity; and * willing to give informed consent and comply with the trial protocol. exclusion criteria: * currently receiving psychotherapy or participating in other clinical trials for insomnia; * pregnancy; * shift workers; * at significant suicidal risk as rated by the hamilton depression rating scale item on suicide (score ≥ 3); * no comorbid sleep disorders primarily requiring other treatment, such as sleep apnea or narcolepsy; and * taking herbal remedies, over-the-counter medication, or psychotropic drugs that target insomnia within the 2 weeks prior to baseline.
membranous nephropathy-associated serological antibody predict the prognosis of idiopathic membranous nephropathy

Conditions: Idiopathic Membranous Nephropathy

Summary: idiopathic membranous nephropathy (imn) remains a common cause of the nephrotic syndrome in adults and one of the leading known causes of end-stage renal disease. identification of circulating autoantigens provide potential biomarkers for diagnosis and therapy of idiopathic membranous nephropathy. m-type phospholipase a2 receptor (pla2r) and thrombospondin type-i domain-containing 7a (thsd7a) were identified as the target antigen in membranous nephropathy with high specificity and the concentration of serum anti-pla2r antibody and anti-tshd7a antibody were helpful for predicting disease activity. in our prospective cohort study, hospitalized patients diagnosed as imn are prospectively studied. circulating anti-pla2r antibody and anti-thsd7a antibodies were recently screened by using enzyme-linked sorbent assay(elisa). this study aims to analyse the difference of clinicopathological characteristics for different concentrations of serum anti pla2r antibody and anti tshd7a antibody, and analyze the association between baseline concentrations of serum antibody and disease activity. this study also explored the prediction effects of serum antibody concentrations with different types of therapeutic regimen in imn and compare the curative effects of different types of therapeutic regimen in different serum antibody concentrations.


Eligibility criteria:
inclusion criteria: * (1) patients who provided informed consent * (2) patients who are diagnosed as membranous nephropathy by renal biopsy * (3) 18 years of age or older, male or female exclusion criteria: * (1) identification of secondary factors such as infectious diseases, rheumatic diseases, tumors, drugs and so on * (2) previous medicine history of immunosuppressive medication and corticosteroids * (3) patients who are not expected to complete 6 months of follow-up
perceptions of e-cigarettes and synthetic cooling agents, the ice study

Conditions: Abuse Tobacco; Exposure

Summary: this study evaluates how synthetic cooling additives like ws-3 and ws-23 impact e-cigarette perceptions, use behavior, and toxicant exposure.

primary objectives: i. assess the abuse liability of e-liquids with and without the presence of synthetic cooling agents. ii. determine the impact of synthetic cooling agents and flavor on ec puffing behavior (topography). iii. determine the exposure ranges (harmful and potentially harmful constituents \[hphcs\], other toxicants) from vaping e-liquids with and without the presence of synthetic cooling agents. outline: participants attend 4 sessions where they receive 1 of 4 randomly assigned flavored e-cigarettes. participants use the e cigarettes for vaping followed by ad libitum vaping. participants also complete surveys and undergo biosample collection throughout the study.

Eligibility criteria:
inclusion criteria: * aged 21-29 years * current exclusive e-cigarette (ec) user (defined as ≥ weekly use over the past 3 months) * willing to provide informed consent and abstain from using their ec at least 12 hours prior to the four lab sessions * read and speak english exclusion criteria: * recently covid-19+ (defined as positive test in the past 30 days) or a recent covid-19 hospitalization (defined as a hospitalization within the past 6 months) * unstable or significant psychiatric conditions (past and stable conditions will be allowed) * history of cardiac event or distress within the past 3 months * are currently pregnant, planning to become pregnant, or breastfeeding (will be verified with urine pregnancy test) * have suffered from any serious lung disease or infection (e.g. , tuberculosis, cystic fibrosis, or lung cancer) in the past 30 days * have hemophilia or another type of bleeding disorder * are blind, severely visually impaired, deaf, hard of hearing, or have a severe motor disability